Potential antivirals and antiviral strategies against SARS coronavirus infections
Identifieur interne : 000868 ( Pmc/Checkpoint ); précédent : 000867; suivant : 000869Potential antivirals and antiviral strategies against SARS coronavirus infections
Auteurs : Erik De ClercqSource :
- Expert Review of Anti-Infective Therapy [ 1478-7210 ] ; 2014.
Abstract
There are a number of antivirals as well as antiviral strategies that could be envisaged to prevent or treat severe acute respiratory syndrome (SARS) (or similar) coronavirus (CoV) infections. Targets for the prophylactic or therapeutic interventions include interaction of the spike (S) glycoprotein (S1 domain) with the host cell receptor, fusion of the S2 domain with the host cell membrane, processing of the replicase polyproteins by the virus-encoded proteases (3C-like cysteine protease [3CLpro] and papain-like cysteine protease) and other virus-encoded enzymes such as the NTPase/helicase and RNA-dependent RNA polymerase. Human monoclonal antibody blocking S1 may play an important role in the immunoprophylaxis of SARS. Fusion inhibitors reminiscent of enfuvirtide in the case of HIV may also be developed for SARS-CoV. Various peptidomimetic and nonpeptidic inhibitors of 3CLpro have been described, the best ones inhibiting SARS-CoV replication with a selectivity index greater than 1000. Human interferons, in particular α- and β-interferon, as well as short interfering RNAs could further be pursued for the control of SARS. Various other compounds, often with an ill-defined mode of action but selectivity indexes up to 100, have been reported to exhibit
Url:
DOI: 10.1586/14787210.4.2.291
PubMed: 16597209
PubMed Central: 7105749
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
PMC:7105749Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Potential antivirals and antiviral strategies against SARS coronavirus infections</title><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation><nlm:aff id="AFF0001"></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">16597209</idno><idno type="pmc">7105749</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7105749</idno><idno type="RBID">PMC:7105749</idno><idno type="doi">10.1586/14787210.4.2.291</idno><date when="2014">2014</date><idno type="wicri:Area/Pmc/Corpus">001004</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">001004</idno><idno type="wicri:Area/Pmc/Curation">001004</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">001004</idno><idno type="wicri:Area/Pmc/Checkpoint">000868</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000868</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Potential antivirals and antiviral strategies against SARS coronavirus infections</title><author><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name><affiliation><nlm:aff id="AFF0001"></nlm:aff></affiliation></author></analytic><series><title level="j">Expert Review of Anti-Infective Therapy</title><idno type="ISSN">1478-7210</idno><idno type="eISSN">1744-8336</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>There are a number of antivirals as well as antiviral strategies that could be envisaged to prevent or treat severe acute respiratory syndrome (SARS) (or similar) coronavirus (CoV) infections. Targets for the prophylactic or therapeutic interventions include interaction of the spike (S) glycoprotein (S1 domain) with the host cell receptor, fusion of the S2 domain with the host cell membrane, processing of the replicase polyproteins by the virus-encoded proteases (3C-like cysteine protease [3CLpro] and papain-like cysteine protease) and other virus-encoded enzymes such as the NTPase/helicase and RNA-dependent RNA polymerase. Human monoclonal antibody blocking S1 may play an important role in the immunoprophylaxis of SARS. Fusion inhibitors reminiscent of enfuvirtide in the case of HIV may also be developed for SARS-CoV. Various peptidomimetic and nonpeptidic inhibitors of 3CLpro have been described, the best ones inhibiting SARS-CoV replication with a selectivity index greater than 1000. Human interferons, in particular α- and β-interferon, as well as short interfering RNAs could further be pursued for the control of SARS. Various other compounds, often with an ill-defined mode of action but selectivity indexes up to 100, have been reported to exhibit <italic>in vitro</italic> activity against SARS-CoV: valinomycin, glycopeptide antibiotics, plant lectins, hesperetin, glycyrrhizin, aurintricarboxylic acid, chloroquine, niclosamide, nelfinavir and calpain inhibitors.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Peiris" uniqKey="Peiris">Peiris</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee" uniqKey="Lee">Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ksiazek" uniqKey="Ksiazek">Ksiazek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Drosten" uniqKey="Drosten">Drosten</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kuiken" uniqKey="Kuiken">Kuiken</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fouchier" uniqKey="Fouchier">Fouchier</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Van Der Hoek" uniqKey="Van Der Hoek">van der Hoek</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stadler" uniqKey="Stadler">Stadler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Oxford" uniqKey="Oxford">Oxford</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shigeta" uniqKey="Shigeta">Shigeta</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="De Clercq" uniqKey="De Clercq">De Clercq</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li" uniqKey="Li">Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hofmann" uniqKey="Hofmann">Hofmann</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jia" uniqKey="Jia">Jia</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong" uniqKey="Wong">Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sui" uniqKey="Sui">Sui</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Towler" uniqKey="Towler">Towler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tripet" uniqKey="Tripet">Tripet</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu" uniqKey="Liu">Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhu" uniqKey="Zhu">Zhu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ni" uniqKey="Ni">Ni</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Veiga" uniqKey="Veiga">Veiga</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Simmons" uniqKey="Simmons">Simmons</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barnard" uniqKey="Barnard">Barnard</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Anand" uniqKey="Anand">Anand</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chou" uniqKey="Chou">Chou</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yang" uniqKey="Yang">Yang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lee" uniqKey="Lee">Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Fan" uniqKey="Fan">Fan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Martina" uniqKey="Martina">Martina</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Jain" uniqKey="Jain">Jain</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ghosh" uniqKey="Ghosh">Ghosh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shie" uniqKey="Shie">Shie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Kaeppler" uniqKey="Kaeppler">Kaeppler</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen" uniqKey="Chen">Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Liu" uniqKey="Liu">Liu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen" uniqKey="Chen">Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Shie" uniqKey="Shie">Shie</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chen" uniqKey="Chen">Chen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Gan" uniqKey="Gan">Gan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Barretto" uniqKey="Barretto">Barretto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lindner" uniqKey="Lindner">Lindner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tanner" uniqKey="Tanner">Tanner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tanner" uniqKey="Tanner">Tanner</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Xu" uniqKey="Xu">Xu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng" uniqKey="Cheng">Cheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Guarino" uniqKey="Guarino">Guarino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sui" uniqKey="Sui">Sui</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ter Meulen" uniqKey="Ter Meulen">ter Meulen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Subbarao" uniqKey="Subbarao">Subbarao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang" uniqKey="Zhang">Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wong" uniqKey="Wong">Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Balzarini" uniqKey="Balzarini">Balzarini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cinatl" uniqKey="Cinatl">Cinatl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hensley" uniqKey="Hensley">Hensley</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stroher" uniqKey="Stroher">Ströher</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zheng" uniqKey="Zheng">Zheng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Spiegel" uniqKey="Spiegel">Spiegel</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sainz" uniqKey="Sainz">Sainz</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Loutfy" uniqKey="Loutfy">Loutfy</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Bao" uniqKey="Bao">Bao</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Haagmans" uniqKey="Haagmans">Haagmans</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stevenson" uniqKey="Stevenson">Stevenson</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He" uniqKey="He">He</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhang" uniqKey="Zhang">Zhang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Li" uniqKey="Li">Li</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chang" uniqKey="Chang">Chang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Neuman" uniqKey="Neuman">Neuman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu" uniqKey="Wu">Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Balzarini" uniqKey="Balzarini">Balzarini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Balzarini" uniqKey="Balzarini">Balzarini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vijgen" uniqKey="Vijgen">Vijgen</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Lin" uniqKey="Lin">Lin</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ito" uniqKey="Ito">Ito</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ito" uniqKey="Ito">Ito</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cinatl" uniqKey="Cinatl">Cinatl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hoever" uniqKey="Hoever">Hoever</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="He" uniqKey="He">He</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ya" uniqKey="Ya">Ya</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cushman" uniqKey="Cushman">Cushman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cushman" uniqKey="Cushman">Cushman</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Balzarini" uniqKey="Balzarini">Balzarini</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Schols" uniqKey="Schols">Schols</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sidwell" uniqKey="Sidwell">Sidwell</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Streeter" uniqKey="Streeter">Streeter</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Saijo" uniqKey="Saijo">Saijo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Savarino" uniqKey="Savarino">Savarino</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keyaerts" uniqKey="Keyaerts">Keyaerts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Vincent" uniqKey="Vincent">Vincent</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Keyaerts" uniqKey="Keyaerts">Keyaerts</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Wu" uniqKey="Wu">Wu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yamamoto" uniqKey="Yamamoto">Yamamoto</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chu" uniqKey="Chu">Chu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan" uniqKey="Chan">Chan</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Expert Rev Anti Infect Ther</journal-id><journal-id journal-id-type="iso-abbrev">Expert Rev Anti Infect Ther</journal-id><journal-id journal-id-type="publisher-id">IERZ</journal-id><journal-id journal-id-type="publisher-id">ierz20</journal-id><journal-title-group><journal-title>Expert Review of Anti-Infective Therapy</journal-title></journal-title-group><issn pub-type="ppub">1478-7210</issn><issn pub-type="epub">1744-8336</issn><publisher><publisher-name>Taylor & Francis</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">16597209</article-id><article-id pub-id-type="pmc">7105749</article-id><article-id pub-id-type="publisher-id">11221845</article-id><article-id pub-id-type="doi">10.1586/14787210.4.2.291</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Potential antivirals and antiviral strategies against SARS coronavirus infections</article-title><alt-title alt-title-type="running-title">Antivirals against SARS</alt-title><alt-title alt-title-type="running-title">De Clercq</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>De Clercq</surname><given-names>Erik</given-names></name><xref ref-type="aff" rid="AFF0001"></xref></contrib><aff id="AFF0001">Professor, Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10B-3000 Leuven, Belgium.<email xlink:href="erik.declercq@rega.kuleuven.be">erik.declercq@rega.kuleuven.be</email></aff></contrib-group><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="epub"><day>10</day><month>1</month><year>2014</year></pub-date><volume>4</volume><issue>2</issue><fpage seq="14">291</fpage><lpage>302</lpage><permissions><copyright-statement>© Future Drugs Ltd</copyright-statement><copyright-year>2006</copyright-year><copyright-holder>Future Drugs Ltd</copyright-holder><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IERZ_4_11221845.pdf"></self-uri><abstract><p>There are a number of antivirals as well as antiviral strategies that could be envisaged to prevent or treat severe acute respiratory syndrome (SARS) (or similar) coronavirus (CoV) infections. Targets for the prophylactic or therapeutic interventions include interaction of the spike (S) glycoprotein (S1 domain) with the host cell receptor, fusion of the S2 domain with the host cell membrane, processing of the replicase polyproteins by the virus-encoded proteases (3C-like cysteine protease [3CLpro] and papain-like cysteine protease) and other virus-encoded enzymes such as the NTPase/helicase and RNA-dependent RNA polymerase. Human monoclonal antibody blocking S1 may play an important role in the immunoprophylaxis of SARS. Fusion inhibitors reminiscent of enfuvirtide in the case of HIV may also be developed for SARS-CoV. Various peptidomimetic and nonpeptidic inhibitors of 3CLpro have been described, the best ones inhibiting SARS-CoV replication with a selectivity index greater than 1000. Human interferons, in particular α- and β-interferon, as well as short interfering RNAs could further be pursued for the control of SARS. Various other compounds, often with an ill-defined mode of action but selectivity indexes up to 100, have been reported to exhibit <italic>in vitro</italic> activity against SARS-CoV: valinomycin, glycopeptide antibiotics, plant lectins, hesperetin, glycyrrhizin, aurintricarboxylic acid, chloroquine, niclosamide, nelfinavir and calpain inhibitors.</p></abstract><kwd-group kwd-group-type="author"><title>Keywords:</title><kwd>coronavirus</kwd><kwd>interferon</kwd><kwd>monoclonal antibody</kwd><kwd>protease inhibitors</kwd><kwd>SARS</kwd><kwd>SARS-CoV inhibitors</kwd><kwd>siRNA</kwd><kwd>S protein</kwd></kwd-group><counts><fig-count count="14"></fig-count><table-count count="0"></table-count><ref-count count="94"></ref-count><page-count count="12"></page-count></counts></article-meta></front></pmc><affiliations><list></list><tree><noCountry><name sortKey="De Clercq, Erik" sort="De Clercq, Erik" uniqKey="De Clercq E" first="Erik" last="De Clercq">Erik De Clercq</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Pmc/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000868 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd -nk 000868 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Pmc
|étape= Checkpoint
|type= RBID
|clé= PMC:7105749
|texte= Potential antivirals and antiviral strategies against SARS coronavirus infections
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/RBID.i -Sk "pubmed:16597209" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |